{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:54:24Z","timestamp":1787313264639,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To evaluate how antireflux surgery influences the risk of esophageal cancer in patients with gastroesophageal reflux disease (GERD) and Barrett esophagus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>GERD is a major risk factor for esophageal adenocarcinoma, and the United Kingdom has the highest incidence of esophageal adenocarcinoma globally.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Hospital Episode Statistics database was used to identify all patients in England aged over 18 years diagnosed with GERD with or without Barrett Esophagus from 2000 to 2012, with antireflux surgery being the exposure investigated. The Clinical Practice Research Datalink (CPRD) was used to provide a sensitivity analysis comparing proton pump inhibitor therapy and antireflux surgery. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox proportional hazards model with inverse probability weights based on the probability of having surgery to adjust for selection bias and confounding factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>(i) Hospital Episode Statistics analysis; among 838,755 included patients with GERD and 28,372 with Barrett esophagus, 22,231 and 737 underwent antireflux surgery, respectively. In GERD patients, antireflux surgery reduced the risk of esophageal cancer (HR = 0.64; 95% CI 0.52\u20130.78). In Barrett esophagus patients, the corresponding HR was (HR = 0.47; 95% CI 0.12\u20131.90).<\/jats:p>\n            <jats:p>(ii) CPRD analysis; antireflux surgery was associated with decreased point estimates of esophageal adenocarcinoma in patients with GERD (0% vs. 0.2%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.16) and Barrett esophagus (HR = 0.75; 95% CI 0.21\u20132.63), but these were not statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Antireflux surgery may be associated with a reduced risk of esophageal cancer risk, however it remains primarily an operation for symptomatic relief.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/sla.0000000000002890","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T23:40:01Z","timestamp":1532562001000},"page":"861-867","source":"Crossref","is-referenced-by-count":21,"title":["The Influence of Antireflux Surgery on Esophageal Cancer Risk in England"],"prefix":"10.1097","volume":"268","author":[{"given":"Sheraz R.","family":"Markar","sequence":"first","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanpreet","family":"Arhi","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Leusink","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Vidal-Diez","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"},{"name":"Molecular and Clinical Sciences Institute, St George's University of London, Cranmer Terrace, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Karthikesalingam","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Institute, St George's University of London, Cranmer Terrace, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Darzi","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Lagergren","sequence":"additional","affiliation":[{"name":"School of Cancer and Pharmaceutical Sciences, King's College London, London, UK"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230923","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.1991.03460100089030","article-title":"Rising incidence of adenocarcinoma of the esophagus and gastric cardia","volume":"265","author":"Blot","year":"1991","journal-title":"JAMA"},{"key":"R2-20230923","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"R3-20230923","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J Clin Oncol"},{"key":"R6-20230923","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJM199903183401101","article-title":"Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma","volume":"340","author":"Lagergren","year":"1999","journal-title":"N Engl J Med"},{"key":"R7-20230923","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1136\/gut.2004.041558","article-title":"Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?","volume":"54","author":"Fitzgerald","year":"2005","journal-title":"Gut"},{"key":"R8-20230923","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/gut.51.3.316","article-title":"Inflammatory gradient in Barrett's oesophagus: implications for disease complications","volume":"51","author":"Fitzgerald","year":"2002","journal-title":"Gut"},{"key":"R9-20230923","doi-asserted-by":"crossref","first-page":"h3169","DOI":"10.1136\/bmj.h3169","article-title":"What is the most effective treatment for severe gastro-oesophageal reflux disease?","volume":"350","author":"Maret-Ouda j","year":"2015","journal-title":"BMJ"},{"key":"R10-20230923","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.2011.626","article-title":"Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial","volume":"305","author":"Galmiche","year":"2011","journal-title":"JAMA"},{"key":"R11-20230923","doi-asserted-by":"crossref","first-page":"f1908","DOI":"10.1136\/bmj.f1908","article-title":"Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX)","volume":"346","author":"Grant","year":"2013","journal-title":"BMJ"},{"key":"R12-20230923","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11938-017-0115-5","article-title":"Clinical implications of emerging data on the safety of proton pump inhibitors","volume":"15","author":"Schnoll-Sussman","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"key":"R13-20230923","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jgh.13737","article-title":"Proton pump inhibitors: risks of long-term use","volume":"32","author":"Eusebi","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"R14-20230923","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","article-title":"Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study","volume":"67","author":"Cheung","year":"2018","journal-title":"Gut"},{"key":"R15-20230923","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2010.01.004","article-title":"The risk of esophageal adenocarcinoma after antireflux surgery","volume":"138","author":"Lagergren","year":"2010","journal-title":"Gastroenterology"},{"key":"R16-20230923","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/SLA.0000000000001438","article-title":"Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis","volume":"263","author":"Maret-Ouda","year":"2016","journal-title":"Ann Surg"},{"key":"R18-20230923","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"R19-20230923","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2001.29569","article-title":"Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery","volume":"121","author":"Ye","year":"2001","journal-title":"Gastroenterology"},{"key":"R20-20230923","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1572-0241.2005.41007.x","article-title":"Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a veterans affairs cohort study","volume":"100","author":"Tran","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R21-20230923","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.285.18.2331","article-title":"Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial","volume":"285","author":"Spechler","year":"2001","journal-title":"JAMA"},{"key":"R22-20230923","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/bjs.10141","article-title":"Mortality from laparoscopic antireflux surgery in a nationwide cohort of the working-age population","volume":"103","author":"Maret-Ouda","year":"2016","journal-title":"Br J Surg"},{"key":"R23-20230923","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jama.2013.226450","article-title":"Barrett esophagus and risk of esophageal cancer: a clinical review","volume":"310","author":"Spechler","year":"2013","journal-title":"JAMA"},{"key":"R24-20230923","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.SLA.0000055269.77838.8E","article-title":"Long-term results of a randomized prospective study comparing medical and surgical treatment of Barret's esophagus","volume":"237","author":"Parrilla","year":"2003","journal-title":"Ann Surg"},{"key":"R25-20230923","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/bjs.1800791021","article-title":"Barrett's oesophagus: effect of antireflux surgery on symptom control and development of complications","volume":"79","author":"Attwood","year":"1992","journal-title":"Br J Surg"},{"key":"R26-20230923","first-page":"A121","article-title":"Role of anti-reflux surgery against dysplasia in Barrett's esophagus","volume":"100","author":"McCallum","year":"1991","journal-title":"Gastroenterology"},{"key":"R27-20230923","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1055\/s-0032-1312922","article-title":"The role of bile acids in the neoplastic progression of Barrett's esophagus: a short representative overview","volume":"50","author":"Jurgens","year":"2012","journal-title":"Z Gastroenterol"},{"key":"R28-20230923","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.2011.626","article-title":"Laparoscopic antireflux surgery vs. esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial","volume":"305","author":"Galmiche","year":"2011","journal-title":"JAMA"},{"key":"R29-20230923","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jama.2017.10981","article-title":"Association between laparoscopic antireflux surgery and recurrence of gastroesophageal reflux","volume":"318","author":"Maret-Ouda","year":"2017","journal-title":"JAMA"}],"container-title":["Annals of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000658-201811000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T06:07:43Z","timestamp":1695449263000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000658-201811000-00021"}},"subtitle":["National Population-based Cohort Study"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/sla.0000000000002890","relation":{},"ISSN":["0003-4932","1528-1140"],"issn-type":[{"value":"0003-4932","type":"print"},{"value":"1528-1140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}